[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367364-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367364-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","immune-checkpoint-molecules-a-review-on-pathways-and-immunotherapy-implications","Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications","","Monoclonal antibody–based cancer therapy targeting immune checkpoints represents a leading immunotherapeutic strategy. Immune checkpoints are regulatory molecules that, when displayed on cancer cells, enable immune evasion through their specific signaling pathways. Counterbalancing checkpoint–related responses with checkpoint antibodies can prevent this evasion. This narrative review summarizes immune checkpoint pathways, outlines immune checkpoint inhibitors, and highlights recent advances and prospects for improving treatment options across prevalent cancers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/immune-checkpoint-molecules-a-review-on-pathways-and-immunotherapy-implications/367364/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/immune-checkpoint-molecules-a-review-on-pathways-and-immunotherapy-implications/367364.png","ImageObject",300,407,{"name":42,"@type":43},"Jacob","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role do immune checkpoints play in cancer immune evasion?","Question",{"text":63,"@type":64},"Immune checkpoints are regulatory molecules whose presence on cancer cells enables immune evasion via their specific pathways.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which immune checkpoint inhibitors are highlighted in the review?",{"text":68,"@type":64},"The review focuses on CTLA-4, PD-1, PD-L1, and other checkpoint family members such as LAG-3, TIM-3, TIGIT, and BTLA.",{"name":70,"@type":61,"acceptedAnswer":71},"How does immune checkpoint blockade compare with conventional cancer therapies?",{"text":72,"@type":64},"Checkpoint blocking is described as producing longer-lasting responses, potentially due to immune system memory, though response rates remain limited and side effects can occur.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367364,1790866208,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962084931830,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Immunity, Inflammation and Disease  \nREVIEW ARTICLE   \nImmune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications  \nErfan Rezazadeh‐Gavgani1 | Reza Majidazar1 | Parisa Lotfinejad2,3  | Tohid Kazemi2,3 | Ali Shamekh1,4   \n1Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran | 2Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran | 3Department of Immunology, Tabriz University of Medical Sciences, Tabriz, Iran | 4Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran  \nCorrespondence: Tohid Kazemi ([kezemit@tbzmed.ac.ir](kezemit@tbzmed.ac.ir)) | Ali Shamekh ([shamekh98@gmail.com](shamekh98@gmail.com); [shamekha@tbzmed.ac.ir](shamekha@tbzmed.ac.ir))  \nReceived: 7 May 2024 | Revised: 12 March 2025 | Accepted: 27 March 2025  \nFunding: This research was supported by the Student Research Committee, Tabriz University of Medical Sciences (Grant Number: 67949) .  \nKeywords: CTLA‐4 | immune checkpoint inhibitor (ICI) | immune modulators | immunotherapy | PD‐1 | PD‐L1  \nABSTRACT  \nBackground: Today, treating cancer patients with monoclonal antibodies (mAbs), by targeting immune checkpoints, is one of the most outstanding immunotherapeutic methods. Immune checkpoints are special molecules having regulatory role in immune system responses. Once these molecules are presented on cancer cells, these cells will be capable of evading the immune system through their own specific pathways. This Evasion can be prevented by counterbalancing immune system responses with immune checkpoints related antibodies.  \nAims: The current study aimed to highlight immunotherapy and its methods, describe the immune checkpoints pathways, outline the immune checkpoint inhibitors (ICIs), and recent advances in this field, and sketch an outlook on the best treatment options for the most prevalent cancers.  \nMaterials & Methods: This research implemented a narrative review method. A comprehensive literature review on the history, molecular and cellular biology, and the clinical aspects of immune checkpoint molecules was performed to illustrate the pathways involved in various cancers. Also, currently‐available and future potential immunotherapies targeting these pathways were extracted from the searched studies.  \nResults: The immune checkpoint family consists of many molecules, including CTLA‐4, PD‐1, PD‐L1, LAG‐3, TIM‐3, and TIGIT. Attempts to modify these molecules in cancer treatment led to the development of therapeutic monoclonal antibodies. Most of these antibodies have entered clinical studies and some of them have been approved by the Food and Drug Administration (FDA) to be used in cancer patients' treatment plans.  \nDiscussion: With these novel treatments and the combination therapies they offer, there is also hope for better treatment outcomes for the previously untreatable metastatic cancers. In spite of the beneficial aspects of immune checkpoint therapy, similar to other treatments, they may cause side effects in some patients. Therefore, more studies are needed to reduce the probable side effects and uncover their underlying mechanism.  \nConclusion: Based on the data shown in this review, there is still a lack of knowledge about the complete properties of ICIs and the possible combination therapies that we may be able to implement to achieve a better treatment response in cancer patients.  \n\n| Erfan Rezazadeh‐Gavgani and Reza Majidazar have equally contributed to this work and should be considered as joint first authors. Tohid Kazemi and Ali Shamekh have equally contributed to this work and should be considered as joint corresponding authors. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\u003Cbr>© 2025 The Author(s) . Immunity, Inflammation and Disease published by John Wiley & Sons Ltd. |\n\nImmu","cbCaipMudJUiEXuX","https://ap.wps.com/l/cbCaipMudJUiEXuX","pdf",870129,18,"English","# Introduction\n## Immune checkpoints and immune evasion\n# Review Scope and Methods\n## Narrative review approach and literature coverage\n# Immune checkpoint molecules and clinical implications\n## CTLA-4, PD-1, PD-L1 and related pathways\n## Therapeutic monoclonal antibodies and FDA-approved use\n# Discussion\n## Combination therapies, benefits, and adverse effects\n# Conclusion","[{\"question\":\"What role do immune checkpoints play in cancer immune evasion?\",\"answer\":\"Immune checkpoints are regulatory molecules whose presence on cancer cells enables immune evasion via their specific pathways.\"},{\"question\":\"Which immune checkpoint inhibitors are highlighted in the review?\",\"answer\":\"The review focuses on CTLA-4, PD-1, PD-L1, and other checkpoint family members such as LAG-3, TIM-3, TIGIT, and BTLA.\"},{\"question\":\"How does immune checkpoint blockade compare with conventional cancer therapies?\",\"answer\":\"Checkpoint blocking is described as producing longer-lasting responses, potentially due to immune system memory, though response rates remain limited and side effects can occur.\"}]","Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications | PDF",1790170486,45,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ea958904b7e494d5920fb67e851dd210.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e7f8dba43b3eb9e71deab3b99542218b.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c6bb83ac30a6f83da98d5ca6f9d80654.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cbf2410f8579b33b36d55876b0d1d936.webp",980,1287]